Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Glutamate signalling: A multifaceted modulator of oligodendrocyte lineage cells in health and disease.
Ubiquitination of RORγt at Lysine 446 Limits Th17 Differentiation by Controlling Coactivator Recruitment.
IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.
Age at onset and seizure frequency affect white matter diffusion coefficient in patients with mesial temporal lobe epilepsy.
Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.
Pseudo-Foster Kennedy Syndrome as a Rare Presentation of Vitamin B12 Deficiency.
Fampridine and quality of life in individuals with multiple sclerosis.
Relapsed Acute Lymphoblastic Leukemia Presenting as Optic Neuritis.
Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.
Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade.
Mercy killing in neurology: The beginnings of neurology on screen (II).
Development of rheumatoid arthritis during treatment of multiple sclerosis with interferon beta 1-a. Coincidence of two conditions or a complication of treatment: A case report.
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
[Cell depletion and myoablation for neuroimmunological diseases].
Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.
Weighted-SAMGSR: combining significance analysis of microarray-gene set reduction algorithm with pathway topology-based weights to select relevant genes.
Cellular mechanisms of adaptive myelination: bridging the gap between animal studies and human cognition.
Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases.
Corrigendum.
Pathology and MRI: exploring cognitive impairment in MS.
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.
Cutaneous and Mixed Nerve Silent Period Recordings in Symptomatic Paroxysmal Kinesigenic Dyskinesia.
[Diagnostics and treatment of trigeminal neuralgia].
Neuropathic pruritus as the p]resenting symptom of lupus transverse myelitis.
Pages
« first
‹ previous
…
773
774
775
776
777
778
779
780
781
…
next ›
last »